Terms: = Prostate cancer AND CBL, RNF55, 867, ENSG00000110395, C-CBL, CBL2 AND Treatment
26 results:
1. PSMA PET/MR is a New Imaging Option for Identifying Glioma Recurrence and Predicting Prognosis.
Xiong M; Chen Z; Zhou C; Yang X; Hu W; Jiang Y; Zheng R; Fan W; Mou Y; Lin X
Recent Pat Anticancer Drug Discov; 2024; 19(3):383-395. PubMed ID: 38214322
[TBL] [Abstract] [Full Text] [Related]
2. Oligometastatic prostate cancer Treated with Stereotactic Body Radiation Therapy: The Role of Three-Dimensional Tumour Volume in Patient Survival.
Franzese C; Lucchini R; Roghi M; Badalamenti M; Baldaccini D; Comito T; Franceschini D; Navarria P; Di Cristina L; Lo Faro L; Galdieri C; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
Clin Oncol (R Coll Radiol); 2023 Dec; 35(12):e649-e656. PubMed ID: 37775459
[TBL] [Abstract] [Full Text] [Related]
3. Inhibition of CDKL3 downregulates STAT1 thus suppressing prostate cancer development.
Jiang Q; Li J; Wang J; Zhang W
Cell Death Dis; 2023 Mar; 14(3):189. PubMed ID: 36899018
[TBL] [Abstract] [Full Text] [Related]
4. A pilot study of MRI radiomics for high-risk prostate cancer stratification in 1.5 T MR-guided radiotherapy.
Zhou Y; Yuan J; Xue C; Poon DMC; Yang B; Yu SK; Cheung KY
Magn Reson Med; 2023 May; 89(5):2088-2099. PubMed ID: 36572990
[TBL] [Abstract] [Full Text] [Related]
5. Financial Toxicity and Its Association With prostate and Colon cancer Screening.
Herriges MJ; Shenhav-Goldberg R; Peck JI; Bhanvadia SK; Morgans A; Chino F; Chandrasekar T; Shapiro O; Jacob JM; Basnet A; Bratslavsky G; Goldberg H
J Natl Compr Canc Netw; 2022 Sep; 20(9):981-988. PubMed ID: 36075394
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors.
Yazgan SC; Yekedüz E; Utkan G; Ürün Y
Prostate; 2022 Nov; 82(15):1456-1461. PubMed ID: 35899494
[TBL] [Abstract] [Full Text] [Related]
7. Artificial intelligence is a promising prospect for the detection of prostate cancer extracapsular extension with mpMRI: a two-center comparative study.
Hou Y; Zhang YH; Bao J; Bao ML; Yang G; Shi HB; Song Y; Zhang YD
Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):3805-3816. PubMed ID: 34018011
[TBL] [Abstract] [Full Text] [Related]
8. Synthesis and evaluation of a novel nanosized anionic linear globular dendrimer G2-ciprofloxacin conjugate against prostate cancer.
Teyhoo M; Hosseini F; Ardestani MS; Ghorbani M
Pak J Pharm Sci; 2020 Nov; 33(6):2589-2594. PubMed ID: 33867334
[TBL] [Abstract] [Full Text] [Related]
9. Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
Wang X; Hui Y; Wang S; Hu X; Yu X; Wang W; Zhang X; Liu L
J Pharm Pharm Sci; 2020; 23():451-461. PubMed ID: 33217255
[TBL] [Abstract] [Full Text] [Related]
10. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant prostate cancer.
Guan X; Sun D; Lu E; Urrutia JA; Reiter RE; Rettig M; Evans CP; Lara P; Gleave M; Beer TM; Thomas GV; Huang J; Aggarwal RR; Quigley DA; Foye A; Chen WS; Youngren J; Weinstein AS; Stuart JM; Feng FY; Small EJ; Xia Z; Alumkal JJ
Clin Cancer Res; 2020 Sep; 26(17):4616-4624. PubMed ID: 32727885
[TBL] [Abstract] [Full Text] [Related]
11. Weighted Gleason Grade Group (WGGG): A new prostate cancer biopsy reporting system with prognostic potential.
Waingankar N; Martini A; Griffiths L; Shah P; Paulucci DJ; Kotamarti S; Gul Z; Elmasri M; Yaskiv O; Haines K; Lerner S; Vira M; Kavoussi LR; Tewari AK; Kapoor DA; Olsson CA
Urol Oncol; 2020 Mar; 38(3):78.e15-78.e21. PubMed ID: 31796374
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.
Thibault C; Eymard JC; Birtle A; Krainer M; Baciarello G; Fléchon A; Le Moulec S; Spaeth D; Laguerre B; Caffo O; Deville JL; Beuzeboc P; Hasbini A; Gross-Goupil M; Helissey C; Bennamoun M; Hardy-Bessard AC; Oudard S
Eur J Cancer; 2018 Jul; 97():41-48. PubMed ID: 29636272
[TBL] [Abstract] [Full Text] [Related]
13. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.
Kote-Jarai Z; Mikropoulos C; Leongamornlert DA; Dadaev T; Tymrakiewicz M; Saunders EJ; Jones M; Jugurnauth-Little S; Govindasami K; Guy M; Hamdy FC; Donovan JL; Neal DE; Lane JA; Dearnaley D; Wilkinson RA; Sawyer EJ; Morgan A; Antoniou AC; Eeles RA;
Ann Oncol; 2015 Apr; 26(4):756-761. PubMed ID: 25595936
[TBL] [Abstract] [Full Text] [Related]
14. Obligatory information that a patient diagnosed of prostate cancer and candidate for an active surveillance protocol must know.
Rubio-Briones J; Iborra I; Ramírez M; Calatrava A; Collado A; Casanova J; Domínguez-Escrig J; Gómez-Ferrer A; Ricós JV; Monrós JL; Dumont R; López-Guerrero JA; Salas D; Solsona E
Actas Urol Esp; 2014 Nov; 38(9):559-65. PubMed ID: 24636075
[TBL] [Abstract] [Full Text] [Related]
15. [Salvage radiotherapy outcomes for biochemical recurrence following radical prostatectomy among the African-Caribbean population of Guadeloupe].
Agoua NG; Vian E; Dumoulin M; Blanchet P
Prog Urol; 2013 Feb; 23(2):128-36. PubMed ID: 23352306
[TBL] [Abstract] [Full Text] [Related]
16. Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study.
Shimabukuro T; Sakano S; Matsuda K; Kamiryo Y; Yamamoto N; Kaneda Y; Nasu T; Baba Y; Suga A; Yamamoto M; Aoki A; Takai K; Yoshihiro S; Konishi M; Imoto K; Matsuyama H
Int J Clin Oncol; 2013 Feb; 18(1):62-7. PubMed ID: 22068464
[TBL] [Abstract] [Full Text] [Related]
17. Clinicopathological strategies to identify contralateral prostate cancer involvement in potential candidates for focal therapy.
Grover S; Srivastava A; Tan G; Sooriakumaran P; John M; Mudaliar K; El-Douaihy Y; Leung R; Shevchuk M; Tewari AK
Int J Surg Pathol; 2010 Dec; 18(6):499-507. PubMed ID: 20732911
[TBL] [Abstract] [Full Text] [Related]
18. Historical perspectives and trends in the management of pain for cancer patients in oman.
Mahfudh SS
Asian Pac J Cancer Prev; 2010; 11 Suppl 1():93-6. PubMed ID: 20590357
[TBL] [Abstract] [Full Text] [Related]
19. Using cone-beam computed tomography to evaluate the impact of bladder filling status on target position in prostate radiotherapy.
Tsai CL; Wu JK; Wang CW; Hsu FM; Lai MK; Cheng JC
Strahlenther Onkol; 2009 Sep; 185(9):588-95. PubMed ID: 19756425
[TBL] [Abstract] [Full Text] [Related]
20. Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study.
Hirano D; Nagane Y; Satoh K; Mochida J; Sugimoto S; Ichinose T; Takahashi S; Maebayashi T; Saitoh T
Int Urol Nephrol; 2010 Mar; 42(1):81-8. PubMed ID: 19449118
[TBL] [Abstract] [Full Text] [Related]
[Next]
